Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Class A ordinary share, par value $0.0001 per share
-
Shares outstanding
-
71,400,541
-
Total 13F shares
-
58,433,271
-
Share change
-
+2,322,943
-
Total reported value
-
$3,528,831,635
-
Put/Call ratio
-
104%
-
Price per share
-
$60.39
-
Number of holders
-
124
-
Value change
-
+$147,969,282
-
Number of buys
-
84
-
Number of sells
-
61
Institutional Holders of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) as of Q4 2023
As of 31 Dec 2023,
MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) was held by
124 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
58,433,271 shares.
The largest 10 holders included
BVF INC/IL, Cormorant Asset Management, LP, FMR LLC, Avoro Capital Advisors LLC, PRICE T ROWE ASSOCIATES INC /MD/, CITADEL ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., T. Rowe Price Investment Management, Inc., FEDERATED HERMES, INC., and Darwin Global Management, Ltd..
This page lists
124
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.